Trial
NCT03712787
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AbbVie
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Tilavonemab
Why stopped
Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-22